Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

568P - FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Neuroendocrine Neoplasms

Presenters

Caroline Lacombe

Citation

Annals of Oncology (2021) 32 (suppl_5): S621-S625. 10.1016/annonc/annonc700

Authors

C. Lacombe1, M. Perrier2, O. Hentic1, H. Brixi2, V. Rebours1, G. Cadiot2, P. Ruszniewski1, L. de Mestier1

Author affiliations

  • 1 Department Of Gastroenterology-pancreatology,beaujon Hospital, Université de Paris, 92110 - Clichy/FR
  • 2 Department Of Hepatogastroenterology And Digestive Oncology, Robert-debré Hospital, Université de Reims-Champagne-Ardenne, 51100 - Reims/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 568P

Background

Well-differentiated neuroendocrine tumors (NETs) are relatively rare, highly vascularized neoplasms. Antiangiogenic drugs have shown efficacy in patients with advanced NETs, although the efficacy of FOLFOX-bevacizumab has been scarcely described in this setting. Hence, we aimed to report its efficacy and tolerance in patients with metastatic NETs.

Methods

We retrospectively studied the records of all consecutive patients with metastatic well-differentiated digestive or lung NETs, treated by FOLFOX-bevacizumab, in two expert centers, from 2013 to 2020. We analyzed time to treatment failure (TTF), objective response (OR) rate and toxicity. We assessed factors associated with TTF and OR using multivariate Cox proportional hazard or logistic regression models, respectively.

Results

We included 57 patients (65% male, median age 62 years), with mostly pancreatic (67%), small-intestine (14%) or lung (7%) NETs. Most patients (58%) had extra-hepatic metastases, including bone metastases in 35% of cases, and median Ki-67 index was 18% (G3 NETs, 40%). Patients had either progressive disease (82%) or were treated on first line (18%). Patients received a median of 17 cycles of FOLFOX-bevacizumab (interquartile range, 9-31), including a median 10 cycles of bevacizumab and/or LV5FU2 maintenance. The median TTF was 15.5 months (95% CI [9.8-21.2]). At multivariate analysis, age >60 years (HR 2.09, 95% CI (1.01-4.33), p=0.048) and >1 previous systemic treatment line (HR 3.55, 95% CI (1.60-7.09), p=0.002) increased the risk of treatment failure. The OR and disease control rates were 43% and 95%, respectively. The OR rate was 53% among pancreatic NETs and was higher in G3 NETs (57%) compared to G2 NETs (33%) and G1 NETs (0%). Performance status at 0 (OR 5.85, 95% CI (1.29-26.53), p=0.022) and G3 NET (OR 5.47, 95% CI (1.26-23.65), p=0.023) independently increased the probability of OR.

Conclusions

The FOLFOX-bevacizumab combination has promising efficacy in patients with progressive metastatic NETs, notably in those with G3 NETs, for which optimal treatment is ill-defined yet. Hence, it could be a relevant alternative to alkylating-based chemotherapy in this setting and should be further explored prospectively.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

APHP.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.